Under the terms of the agreement with Ferring, Ferring will fund development of a custom version of the OmniPod’s Personal Diabetes Manager and, upon completion of the development, will agree to purchase minimum quantities of the OmniPod systems over a five year period, beginning in 2009.
Duane DeSisto, president and CEO of Insulet, said: “We are pleased to partner with Ferring to develop an OmniPod for the delivery of a women’s health treatment, as a first step toward expanded applications of the OmniPod system for drug delivery. We believe the OmniPod system can be an effective platform technology for the delivery of other drugs that require continuous or frequent infusions.”